LEVI-04, a novel neurotrophin-3 inhibitor, significantly improved pain and function in patients with knee osteoarthritis (OA) compared to placebo in a phase 2 trial.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.